BRAIN and NERVE－神経研究の進歩76巻8号

2024年08月発行

総説

Tumefactive demyelinating lesions

著者： 水本悠希¹ 安部鉄也¹

所属機関： ¹山口県立総合医療センター脳神経内科

ページ範囲：P.953 - P.960

文献概要

TDL（Tumefactive demyelinating lesions）は2cm以上の炎症性脱髄性疾患と定義され，多発性硬化症などの経過中に出現し得るが，初発病変としてみられた場合には，鑑別が特に困難となる。腫瘍性，あるいは感染性疾患との鑑別のために，各種画像検査に加えて病理学的検討を要することも多い。本論では，TDLの概念，疫学，診断，治療について概論する。

参考文献

1）van der Velden M, Bots GT, Endtz LJ: Cranial CT in multiple sclerosis showing a mass effect. Surg Neurol 12: 307-310, 1979

2）Lucchinetti CF, Gavrilova RH, Metz I, Parisi JE, Scheithauer BW, et al: Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131: 1759-1775, 2008

3）Fereidan-Esfahani M, Decker PA, Eckel Passow JE, Lucchinetti CF, Flanagan EP, et al: Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States. Eur J Neurol 29: 782-789, 2022

4）Ongphichetmetha T, Aungsumart S, Siritho S, Apiwattanakul M, Tanboon J, et al: Author correction: tumefactive demyelinating lesions: a retrospective cohort study in Thailand. Sci Rep 14: 5332, 2024［doi: 10.1038/s41598-024-56016-2］

5）Fereidan-Esfahani M, Decker PA, Weigand SD, Lopez Chiriboga AS, Flanagan EP, et al: Defining the natural history of tumefactive demyelination: a retrospective cohort of 257 patients. Ann Clin Transl Neurol 10: 1544-1555, 2023

6）Vakrakou AG, Tzanetakos D, Evangelopoulos ME, Argyrakos T, Tzartos JS, et al: Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases. Ther Adv Neurol Disord 14: 17562864211006503, 2021［doi: 10.1177/17562864211006503］

7）Vakrakou AG, Brinia ME, Svolaki I, Argyrakos T, Stefanis L, et al: Immunopathology of tumefactive demyelinating lesions-from idiopathic to drug-related cases. Front Neurol 13: 868525, 2022［doi: 10.3389/fneur.2022.868525］

8）Boyle T, Fernando SL, Drummond J, Fontes A, Parratt J: Phenotyping variants of tumefactive demyelinating lesions according to clinical and radiological features-A case series. Front Neurol 14: 1092373, 2023［doi: 10.3389/fneur.2023.1092373］

9）Erdoğan T, Koçer B, Şen S, Balcı BP, Terzi M: Newly diagnosed tumefactive demyelinating lesion and multiple sclerosis after COVID-19 infection. Noro Psikiyatr Ars 60: 223-230, 2023

10）Hu J, Huang L, Qiu Z, Liu Y, Shen K, et al: Case report: A novel case of COVID-19 triggered tumefactive demyelinating lesions in one multiple sclerosis patient. Front Neurosci 17: 1287480, 2023［doi: 10.3389/fnins.2023.1287480］

11）Araújo VO, Marcelino PFS, Rabelo SR, Junior FASL, Teixeira VGG, et al: Tumefactive demyelination after covid-19 successfully treated with betainterferon 1A. Radiol Case Rep 17: 4123-4127, 2022

12）Kiriyama T, Kataoka H, Taoka T, Tonomura Y, Terashima M, et al: Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm. J Neuroimaging 21: e69-e77, 2011［doi: 10.1111/j.1552-6569.2010.00502.x］

13）Wynne D, Hung Ho BK, Han TF: Tumefactive Demyelination Appearing as Multiple Cystic Brain Lesions. World Neurosurg 153: 6-8, 2021

H-magnetic resonance spectroscopyが診断に有用であった小児多発性硬化症の1例. 臨床神経51: 688-693, 2011

15）Malhotra HS, Jain KK, Agarwal A, Singh MK, Yadav SK, et al: Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy. Mult Scler 15: 193-203, 2009

16）Vakrakou AG, Tzanetakos D, Argyrakos T, Koutsis G, Evangelopoulos ME, et al: Recurrent fulminant tumefactive demyelination with marburg-like features and atypical presentation: therapeutic dilemmas and review of literature. Front Neurol 11: 536, 2020［doi: 10.3389/fneur.2020.00536］

17）Hsu J, Plein A, Mathis SB: Neuropsychiatric manifestations of tumefactive demyelinating lesion. Am J Psychiatry Resid J 18: 9-12, 2023

18）Werneck LC, Scola RH, Arruda WO, Torres LF: Glioma and multiple sclerosis: case report. Arq Neuropsiquiatr 60: 469-474, 2002

19）Sinclair G, Benmakhlouf H, Martin H, Maeurer M, Dodoo E: Adaptive hypofractionated gamma knife radiosurgery in the acute management of brainstem metastases. Surg Neurol Int 10: 14, 2019［doi: 10.4103/sni.sni_53_18］

20）Enriquez-Marulanda A, Valderrama-Chaparro J, Parrado L, Diego Vélez J, Maria Granados A, et al: Cerebral toxoplasmosis in an MS patient receiving Fingolimod. Mult Scler Relat Disord 18: 106-108, 2017

21）Kinon MD, Scoco A, Farinhas JM, Kobets A, Weidenheim KM, et al: Glioblastoma multiforme presenting with an open ring pattern of enhancement on MR imaging. Surg Neurol Int 8: 106, 2017［doi: 10.4103/sni.sni_35_17］

22）Neuroimmunology Group of Neurology Branch of Chinese Medical Association, Neuroimmunology Committee of Chinese Society for Immunology, Immunology Society of Chinese Stroke Association: Chinese Guidelines for the Diagnosis and Management of Tumefactive Demyelinating Lesions of Central Nervous System. Chin Med J (Engl) 130: 1838-1850, 2017

23）Zhang Y, Zhang T, Zhang X, Yan X, Lei J, et al: Clinical spectrum and prognosis of pathologically confirmed atypical tumefactive demyelinating lesions. Sci Rep 13: 7773, 2023［doi: 10.1038/s41598-023-34420-4］

24）Honkaniemi J, Dastidar P, Kähärä V, Haapasalo H: Delayed MR imaging changes in acute disseminated encephalomyelitis. AJNR Am J Neuroradiol 22: 1117-1124, 2001

25）Khurana DS, Melvin JJ, Kothare SV, Valencia I, Hardison HH, et al: Acute disseminated encephalomyelitis in children: discordant neurologic and neuroimaging abnormalities and response to plasmapheresis. Pediatrics 116: 431-436, 2005

26）Mao-Draayer Y, Braff S, Pendlebury W, Panitch H: Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. Neurology 59: 1074-1077, 2002

27）Li X, Miao X, Wang Y, Sun J, Gao H, et al: Central nervous system tumefactive demyelinating lesions: Risk factors of relapse and follow-up observations. Front Immunol 13: 1052678, 2022［doi: 10.3389/fimmu.2022.1052678］

28）Fereidan-Esfahani M, Tobin WO: Cyclophosphamide in treatment of tumefactive multiple sclerosis. Mult Scler Relat Disord 47: 102627, 2021［doi: 10.1016/j.msard.2020.102627］